A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia

Acta Psychiatrica Scandinavica

Volumn 111, Issue 6, 2005, Pages 403-409

  Maidment, Ian D ^a,c   Fox, C ^a   Boustani, M ^b  

^a UNIVERSITY OF KENT   (United Kingdom)

^b REGENSTRIEF INSTITUTE   (United States)

^c KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

Author keywords

Cholinesterase inhibitors; Parkinson's disease; Parkinson's disease dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; TACRINE;

BIBLIOGRAPHIC DATABASE; CINHAL; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; CONFUSION; CONSTIPATION; DAILY LIFE ACTIVITY; DEMENTIA; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EMBASE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPERSALIVATION; MEDLINE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NAUSEA; NEUROPSYCHIATRY; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCINFO; REVIEW; RHINORRHEA; SIDE EFFECT; TREMOR; URINARY FREQUENCY; VOMITING;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; MIDDLE AGED; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS;

EID: 20144369487     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2005.00516.x     Document Type: Review

References (40)

1. AARSLAND D, ANDERSON K, LARSEN JP, LOLK A, NIELSEN H, KRAGH-SORENSEN P. Risk of dementia in Parkinson's disease - a community-based, prospective study. Neurology 2001;56:730-736.
2. NILSSON FM. Psychiatric and cognitive disorders in Parkinson's disease. Curr Opin Psychiatry 2004;17:197-202.
3. AARSLAND D, LAAKE K, LARSEN JP, JANVIN C. Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled trial. J Neurol Neurosurg Psychiatry 2002; 72:708-712.
4. BURN DJ, MCKEITH IG. Current treatment of dementia with Lewy Bodies and Dementia associated with Parkinson's Disease. Mov Disord 2003;18:S72-S79.
5. AARSLAND D, BALLARD C, LARSEN JP, MCKEITH I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-536.
6. MCKEITH IG, GALASKO D, KOSAKA K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
7. LEROI I, BRANDT J, REICH SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.
8. KAASINEN V, NAGREN K, HIETALA J. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000;54:1482-1487.
9. JELLINGER KA, BANCHER CH. Structural basis of mental impairment in Parkinson's disease. Neuropsychiatrie 1995;9:9-14.
10. WERBER EA, RABEY JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neurotrans 2001;108:1319-1325.
11. AARSLAND D, HUTCHINSON M, LARSEN JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:937-941.
12. KULISEVSKY J, GARCIA-SANCHEZ C, BERTHIER ML et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's Disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000;15:613-626.
13. BARBER R, PANIKKER A, MCKEITH IG. Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry 2001;16:S12-S18.
14. GRAHAM JM, SUSSMAN JD, FORD KS, SAGAR HJ. Olanzapine in the treatment of hallucinosis in idiopathic parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998;65:774-777.
15. PERRY EK, CURTIS M, DICK DJ et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413-421.
16. RICHARD IH, JUSTUS AW, GREIG NH, MARSHALL F, KURLAN R. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol 2002;25:296-299.
17. EMRE M, AARSLAND D, ALBANESE A et al. Rivastigmine for Dementia Associated with Parkinson's disease. New Engl J Med 2004;351:2509-2518.
18. GILADI N, SHABTAI H, GUREVICH T, BENBUNAN B, ANCA M, KORCZYN AD. Rivastigmine for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003;108:368-373.
19. READING PJ, LUCE AK, MCKEITH IG. Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001;16:1171-1174.
20. BULLOCK R, CAMERON A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002;18:258-264.
21. BERGMAN J, LERNER V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002;25:107-110.
22. HUTCHINSON M, FAZZINI E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:324-325.
23. AARSLAND D, MOSIMANN UP, MCKEITH IG. Role of cholinesterase Inhibitors in Parkinson's disease and dementia with lewy body. J Geriatr Psychiatry Neurol 2004;17:164-171.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Revised. Washington, DC: American Psychiatric Association, 1994.
25. REISBERG B, FERRIS SH, DE LEON MJ, CROOK T. Global Deterioration Scale. Psychopharmacol Bull 1988;24:661-663.
26. HOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. Mini-Mental State: a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
27. HUGHES AJ, DANIEL SE, KILFORD L, LEES AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
28. DANIEL SE, LEES AJ. Parkinson's disease brain bank, London: overview and research. J Neural Transm 1993;39(suppl.):165-172.
29. FAHN S, ELTON RL. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: FAHN S, MARSDEN CD, CALNE DB et al. eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information, 1987:153-163.
30. ROSEN W, MOHNS R, DAVIS K. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
31. GUY W. ECDEU Assessment Manual for Psychopharmacology, revised. Washington, DC: US Department of Health, Education and Wealth, 1976.
32. SCHEIDER LS, OLIN JT, DOODY RS et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-clinical impression of change. Alzheimer Dis Assoc Disord 1997;11(Suppl. 2):S22-S32.
33. MATTIS S. Dementia Rating Scale (DRS) Professional Manuel. Odessa, FL: Psychological Assessment Resources, Inc., 1988.
34. CUMMINGS JL, MEGA M, GRAY K, ROSENBERG-THOMPSON S, CARUSI DA, GORNBEIN J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
35. ANDREASEN N. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa, 1984.
36. SIMPSON GM, ANGUS JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212(suppl.):11-19.
37. RABEY JM, BASS H, BONNICCELLI U. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 1997;20:322-337.
38. GALASKO D, BENNETT D, SANO M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl. 2):S33-S39.
39. HOEHN MH, YAHR MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
40. PRESS DZ. Editorial: Parkinson's disease dementia - a first step? New Engl J Med 2004;351:2547-2549.